YU29804A - Upotreba aktivatora gp-130 u dijabetskoj neuropatiji - Google Patents

Upotreba aktivatora gp-130 u dijabetskoj neuropatiji

Info

Publication number
YU29804A
YU29804A YU29804A YUP29804A YU29804A YU 29804 A YU29804 A YU 29804A YU 29804 A YU29804 A YU 29804A YU P29804 A YUP29804 A YU P29804A YU 29804 A YU29804 A YU 29804A
Authority
YU
Yugoslavia
Prior art keywords
diabetic neuropathy
activators
medicament
prevention
manufacture
Prior art date
Application number
YU29804A
Other languages
English (en)
Inventor
Michel Dreano
Pierre-Alain Vitte
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of YU29804A publication Critical patent/YU29804A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae

Abstract

Ovaj pronalazak se odnosi na upotrebu supstance koja vrši signalizaciju preko gp130 u proizvodnji medikamenta za lečenje i/ili prevenciju dijabetske neuropatije. Upotreba IL-6 je preferentna.[The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
YU29804A 2001-10-11 2002-10-10 Upotreba aktivatora gp-130 u dijabetskoj neuropatiji YU29804A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123400 2001-10-11

Publications (1)

Publication Number Publication Date
YU29804A true YU29804A (sh) 2006-08-17

Family

ID=8178778

Family Applications (1)

Application Number Title Priority Date Filing Date
YU29804A YU29804A (sh) 2001-10-11 2002-10-10 Upotreba aktivatora gp-130 u dijabetskoj neuropatiji

Country Status (20)

Country Link
US (3) US7465441B2 (sh)
EP (1) EP1434597B1 (sh)
JP (1) JP2005505608A (sh)
KR (1) KR20050035151A (sh)
CN (1) CN1602203A (sh)
AT (1) ATE542542T1 (sh)
AU (1) AU2002340547B2 (sh)
BR (1) BR0213183A (sh)
CA (1) CA2463020A1 (sh)
DK (1) DK1434597T3 (sh)
EA (1) EA006881B1 (sh)
ES (1) ES2381341T3 (sh)
HR (1) HRP20040292A2 (sh)
IL (1) IL161310A0 (sh)
MX (1) MXPA04003442A (sh)
NO (1) NO20041908L (sh)
PL (1) PL369296A1 (sh)
WO (1) WO2003033015A1 (sh)
YU (1) YU29804A (sh)
ZA (1) ZA200402351B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050035151A (ko) * 2001-10-11 2005-04-15 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 당뇨성 신경병증에서 ｇｐ130 활성인자의 용도
ATE549353T1 (de) 2003-05-13 2012-03-15 Merck Serono Sa Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
IL161673A0 (en) * 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2011203356B2 (en) * 2004-04-29 2012-03-22 Yeda Research & Development Co., Ltd IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
CA2681935A1 (en) * 2007-03-30 2008-10-09 Baker Medical Research Institute Treatment of obesity
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN106924736B (zh) * 2017-05-09 2020-01-03 北京师范大学 gp130抑制剂在制备干预和治疗肥胖导致的血糖代谢疾病产品中的应用
FR3080533A1 (fr) * 2018-04-27 2019-11-01 Enterosys Utilisation de l'il-6 pour le traitement du diabete

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
EP1200124B1 (en) 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
KR20050035151A (ko) * 2001-10-11 2005-04-15 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 당뇨성 신경병증에서 ｇｐ130 활성인자의 용도

Also Published As

Publication number Publication date
BR0213183A (pt) 2004-08-31
EA200400520A1 (ru) 2004-08-26
EP1434597B1 (en) 2012-01-25
ES2381341T3 (es) 2012-05-25
EA006881B1 (ru) 2006-04-28
US7465441B2 (en) 2008-12-16
NO20041908L (no) 2004-05-10
PL369296A1 (en) 2005-04-18
ATE542542T1 (de) 2012-02-15
US8278286B2 (en) 2012-10-02
HRP20040292A2 (en) 2005-06-30
ZA200402351B (en) 2005-03-29
US20100189684A1 (en) 2010-07-29
KR20050035151A (ko) 2005-04-15
US20090169506A1 (en) 2009-07-02
JP2005505608A (ja) 2005-02-24
DK1434597T3 (da) 2012-02-27
AU2002340547B2 (en) 2008-04-03
MXPA04003442A (es) 2004-07-08
CN1602203A (zh) 2005-03-30
IL161310A0 (en) 2004-09-27
US20050058623A1 (en) 2005-03-17
CA2463020A1 (en) 2003-04-24
EP1434597A1 (en) 2004-07-07
WO2003033015A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
MY127290A (en) New use of flibanserin
MY129422A (en) Medicinal compounds
MY136707A (en) Thrombopoietin mimetics
BG101831A (en) Valacyclovir tablems containing colloid silicon dioxide
GB0004128D0 (en) Novel compounds
GB0111186D0 (en) Novel compounds
MXPA04003796A (es) Tioacetamidas sustituidas.
IL158867A0 (en) Ostepontin and agonists thereof in treatment and/or prevention of neurological diseases
YU29804A (sh) Upotreba aktivatora gp-130 u dijabetskoj neuropatiji
HK1068606A1 (en) Novel aminobenzoephenones
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
IL159993A0 (en) Platinum complexes and their use in cancer treatment
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
IL130500A (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
MD2053B1 (en) Remedy with interferon inducing action
AU2002234644A1 (en) Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.